trending Market Intelligence /marketintelligence/en/news-insights/trending/cahduJbCre9OdkOh5qJozQ2 content esgSubNav
In This List

Aerie Pharmaceuticals' Rhopressa gets US FDA approval to lower eye pressure

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Aerie Pharmaceuticals' Rhopressa gets US FDA approval to lower eye pressure

The U.S. Food and Drug Administration approved Aerie Pharmaceuticals Inc.'s Rhopressa 0.02% for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The approval was made two months ahead of the scheduled approval date of Feb. 28, 2018.

Previously, an advisory panel for the FDA voted 9-1 in favor of Rhopressa, concluding that its benefits outweigh its risks.